Archives

  • 2026-04
  • 2026-03
  • 2026-02
  • 2026-01
  • 2025-12
  • 2025-11
  • 2025-10

    • DiscoveryProbe™ FDA-approved Drug Library: Enabling High-...

    2025-10-31

    DiscoveryProbe™ FDA-approved Drug Library: Enabling High-Content, High-Throughput Drug Repositioning

    Executive Summary: The DiscoveryProbe™ FDA-approved Drug Library (L1021) comprises 2,320 bioactive compounds approved by the FDA, EMA, HMA, CFDA, or PMDA, or listed in recognized pharmacopeias, facilitating rapid evaluation of clinically relevant molecules (DiscoveryProbe™ product page). The library supports high-throughput and high-content screening for drug repositioning and target identification across oncology, neurodegeneration, and metabolic research (see prior summary). Compounds are provided as 10 mM DMSO solutions in multiple plate/tube formats, stable up to 24 months at -80°C. Mechanistically diverse, the collection encompasses receptor modulators, enzyme inhibitors, and channel regulators, enabling pathway-specific investigation and signal transduction studies (Li et al., 2024). The library is routinely used for screens such as mTORC1 pathway modulation, as validated in live-cell reporter studies.

    Biological Rationale

    Drug discovery increasingly relies on repurposing clinically validated compounds to accelerate translational research (see roadmap). The DiscoveryProbe™ FDA-approved Drug Library provides a unique set of molecules with established human safety and pharmacokinetics. These compounds have defined mechanisms of action, including receptor agonism/antagonism, enzyme inhibition, and modulation of ion channels or signaling molecules. By leveraging drugs with known clinical histories, researchers can rapidly identify candidates for new indications, de-risking the development pipeline.

    Mechanistic pathway screens—such as those targeting mTORC1 signaling in cancer or nutrient-sensing pathways in neurodegeneration—benefit from libraries that span multiple classes of bioactive agents (Li et al., 2024). Key targets include protein kinases, metabolic enzymes, and transcriptional regulators relevant to disease etiology. The inclusion of diverse chemotypes enables unbiased, phenotypic screening as well as hypothesis-driven approaches.

    Mechanism of Action of DiscoveryProbe™ FDA-approved Drug Library

    The DiscoveryProbe™ library includes compounds acting on diverse molecular targets. These include:

    • Receptor agonists and antagonists: Modulate GPCRs, nuclear receptors, and tyrosine kinase receptors.
    • Enzyme inhibitors: Target kinases (e.g., mTOR, S6K), acetylases, deacetylases (e.g., panobinostat), and metabolic enzymes (e.g., metformin inhibits mitochondrial complex I).
    • Ion channel modulators: Affect voltage-gated and ligand-gated channels implicated in neurodegenerative and cardiac disease.
    • Signal pathway regulators: Influence PI3K/AKT, MAPK, mTORC1, Wnt, and other core cascades.

    Representative drugs such as doxorubicin (DNA intercalator), metformin (AMPK activator), and atorvastatin (HMG-CoA reductase inhibitor) illustrate the mechanistic breadth. For example, histone deacetylase (HDAC) inhibitors in this collection have been shown to modulate mTORC1 activity through nutrient-sensing pathways using live-cell sensors (Li et al., 2024).

    Evidence & Benchmarks

    • The DiscoveryProbe™ FDA-approved Drug Library contains 2,320 unique compounds, each with documented regulatory approval or pharmacopoeial listing (product specs).
    • Compounds are pre-dissolved in 10 mM DMSO and stable for 12 months at -20°C or 24 months at -80°C, permitting long-term HTS/HCS workflows (product page).
    • The library has been used to identify mTORC1 inhibitors, including HDAC inhibitors such as panobinostat, confirmed with live-cell fluorescence sensors (Li et al., 2024, DOI).
    • High-content imaging platforms using the DiscoveryProbe™ collection enable pathway-specific screening in cancer and neurodegeneration models (internal review).
    • Compounds cover a wide mechanistic spectrum: receptor targets (30%), enzymes (40%), ion channels (10%), miscellaneous (20%) (catalog data).

    Applications, Limits & Misconceptions

    The DiscoveryProbe™ FDA-approved Drug Library is optimized for applications including:

    • High-throughput screening (HTS) for target/pathway modulation in cancer, metabolic, and neurodegenerative models.
    • High-content screening (HCS) with imaging-based reporters (e.g., live-cell mTORC1 sensors).
    • Drug repositioning screens leveraging clinical data to identify new indications.
    • Mechanism-of-action studies for pathway elucidation and target validation.
    • Pharmacological profiling and benchmarking against standard-of-care compounds.

    This article extends prior summaries (see here) by detailing the mechanistic rationale and providing peer-reviewed evidence for pathway-specific applications in mTORC1 biology.

    Common Pitfalls or Misconceptions

    • Not all compounds are universally effective: Efficacy is context-dependent; compound activity must be validated in each model system (Li et al., 2024).
    • Approved status is not a guarantee of safety in new indications: Off-target or cumulative toxicity may arise in repurposing studies.
    • Mechanism misattribution: Some compounds exhibit pleiotropic effects, complicating mechanistic readouts without orthogonal validation.
    • Concentration and solubility: 10 mM DMSO stock may require dilution to avoid cytotoxicity or precipitation in aqueous systems.
    • HTS artifacts: Autofluorescence or DMSO interference can confound high-content imaging if controls are not included.

    Workflow Integration & Parameters

    The DiscoveryProbe™ FDA-approved Drug Library (L1021) is supplied in formats compatible with automated liquid handling: 96-well microplates, deep-well plates, and 2D barcoded screw-top storage tubes. Compound solutions are pre-dissolved at 10 mM in DMSO and shipped on blue ice for evaluation sizes, or at room temperature/blue ice as specified. Recommended storage is -20°C for up to 12 months or -80°C for up to 24 months.

    HTS and HCS protocols typically use 1–10 µM final compound concentrations, with appropriate DMSO controls. The library integrates with imaging-based workflows, flow cytometry, and molecular assays. Data management is facilitated by 2D barcoding and comprehensive compound annotation. Refer to the DiscoveryProbe™ FDA-approved Drug Library product page for technical documentation and ordering options.

    This article clarifies workflow integration and benchmarking details beyond the scope of earlier discussions (combination therapy use case).

    Conclusion & Outlook

    The DiscoveryProbe™ FDA-approved Drug Library is a validated and versatile tool for high-throughput and high-content drug discovery. Its clinical-grade composition, mechanistic diversity, and robust annotation facilitate advanced applications in oncology, neurodegeneration, and metabolic disease. The inclusion of compounds with proven human safety and pharmacokinetics accelerates the translation from bench to bedside. Ongoing integration with phenotypic screening platforms and live-cell reporters—such as mTORC1 pathway sensors—will further enhance the utility of this collection in uncovering novel therapeutic strategies (Li et al., 2024).